Cochlear (FRA:OC50) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OC50 Cochlear Ltd FRA:OC50
73 GF Score
Price €37.20
GF Value €96.96
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear FFO per Share?

FFO per Share only applies to REITs.

FRA:OC50
73GF Score
Cochlear Ltd FRA:OC50
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cochlear (FRA:OC50) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of €37.20 is trading 61.6% below its estimated GF Value™ of €96.96. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for FRA:OC50:

  • FFO per Share:
  • GF Value™: €96.96 vs. price of €37.20 (61.6% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the FRA:OC50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
73GF Score

Get the complete analysis for FRA:OC50

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.20
Price
€96.96
GF Value